Enjoy complimentary customisation on priority with our Enterprise License!
According to Technavio's analyst, the proteasome inhibitors market size is expected to be valued at USD 2.20 billion by 2026 with a CAGR of 7.4%.
The proteasome inhibitors market has been broadly categorized into the following demographic segmentations:
This proteasome inhibitors market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. The proteasome inhibitors market report offers information on several market vendors, including AbbVie Inc., Accuitis Inc., Amgen Inc., Bristol Myers Squibb Co., Cantex Pharmaceuticals Inc., Fresenius SE and Co. KGaA, Johnson and Johnson, Takeda Pharmaceutical Co. Ltd., and TG Therapeutics Inc. among others.
Download the Free Report Sample to Unlock the Proteasome Inhibitors Market Size for the Forecast Period and Other Important Statistics
The huge unmet need is notably driving the proteasome inhibitors market growth, although factors such as the threat from biologics may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the proteasome inhibitors industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Proteasome Inhibitors Market Driver
One of the key drivers supporting the proteasome inhibitors market growth is the huge unmet need. For instance, the market has a very limited number of therapies approved for the treatment of pancreatic cancer. It is currently the fatal type of cancer globally and ranked the third most fatal cancer in the US. As per NIH, the five-year survival rate of patients with pancreatic cancer in 2021 was 5-10%, and the number of deaths caused by the indication, in 2021, was 5 per 100 people per year globally. Moreover, the market witnesses the presence of various vendors developing proteasome inhibitors in the late stages of clinical trials for multiple myeloma and two drugs for pancreatic cancer. Thus, the unmet need is expected to attract various large and mid-sized pharmaceutical vendors to conduct studies and launch the product, which is expected to help the market grow significantly during the forecast period.
Key Proteasome Inhibitors Market Trend
One of the key proteasome inhibitors market trends fueling the market growth is the expanded application. For instance, VELCADE, the first proteasome inhibitor on the market, is being studied in Phase II stage of clinical trials for the treatment of glioma. Similarly, KYPROLIS by Amgen is being developed in the Phase II stage of clinical trials for the treatment of prostate cancer and renal cell carcinoma. This drug is also being developed for small cell lung cancer and various other solid tumors in Phase I/II stage of clinical trials. NINLARO, Dicopp, oprozomib, and marizomib are some of the other pipeline drugs that are being studied for solid tumor indications. Thus, the presence of a strong pipeline will lead to the expanded application of proteasome inhibitors over the forecast period, which, in turn, will drive proteasome inhibitors market growth.
Key Proteasome Inhibitors Market Challenge
One of the challenges hindering the proteasome inhibitors market growth is the threat from biologics. Various vendors in the global proteasome inhibitors market are developing drugs for the treatment of solid tumors such as pancreatic cancer, malignant melanoma, and others. For instance, AbbVie is developing KYPROLIS in the phase II stage of clinical trials for the treatment of prostate cancer and renal cell carcinoma. Similarly, Takeda is developing VELCADE in the Phase II stage of clinical trials for the treatment of glioma. Significantly, these vendors face a heavy threat of substitutes from an increasing number of highly effective biologics such as PD-1 and PD-L1 inhibitors. Such effectiveness of using biologics will hinder the proteasome inhibitors market growth during the forecast period.
This proteasome inhibitors market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the proteasome inhibitors market encompasses successful business strategies deployed by the key vendors. The proteasome inhibitors market is concentrated and the vendors are deploying growth strategies such as strategic alliances to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The proteasome inhibitors market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
For more insights on the market share of various regions Request for a FREE sample now!
43% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for proteasome inhibitors in North America. However, market growth in this region will be slower than the growth of the market in other regions.
The advanced healthcare infrastructure will facilitate the proteasome inhibitors market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
In 2020, the outbreak of COVID-19 affected the economies of various countries in North America, especially the US, and had a negative impact on regional market growth. However, with the initiation of vaccination drives, the market is expected to grow during the forecast period.
To gain further insights on the market contribution of various segments Request for a FREE sample
The proteasome inhibitors market share growth by the VELCADE segment will be significant during the forecast period. VELCADE is an intravenously administered first-generation proteasome inhibitor, which is a type of targeted therapy developed by Takeda and Johnson and Johnson. This drug inhibits the proteasome enzyme complex within the cell, which is a part of the cellular machinery. The drug also plays a major role in the regulation of cell division and cell survival. Moreover, VELCADE is the first proteasome inhibitor to receive marketing approval in major regions. Such factors of VELCADE will drive the proteasome inhibitors market growth during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the proteasome inhibitors market size and actionable market insights on post COVID-19 impact on each segment.
Technavio categorizes the proteasome inhibitors market as a part of the pharmaceutical market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the proteasome inhibitors market during the forecast period.
Our report provides extensive information on the value chain analysis for the proteasome inhibitors market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
|
Proteasome Inhibitors Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2021 |
|
Forecast period |
2022-2026 |
|
Growth momentum & CAGR |
Decelerate at a CAGR of 7.4% |
|
Market growth 2022-2026 |
$ 2.20 billion |
|
Market structure |
Concentrated |
|
YoY growth (%) |
9.97 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 43% |
|
Key consumer countries |
US, Canada, UK, Germany, and France |
|
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
|
Key companies profiled |
AbbVie Inc., Accuitis Inc., Amgen Inc., Bristol Myers Squibb Co., Cantex Pharmaceuticals Inc., Fresenius SE and Co. KGaA, Johnson and Johnson, Takeda Pharmaceutical Co. Ltd., and TG Therapeutics Inc. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Product
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Customized Report as per your Business Needs
Let us help you make report more suited to your requirements.
Get the report (PDF) sent to your email within minutes.
